Sunday 18 October 2026
Export BIOLQ’s income statement to Excel — free account
Biolase, Inc.
BIOLQ Healthcare Medical Devices
Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow BIOLQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 8,330.94 | 3,500.00 | 2,275.00 | 1,075.00 | 527.50 | 925.00 | 51.30 | 1.07 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | 23,232.76 | 21,942.05 | 7,450.00 | 7,175.00 | 2,400.00 | 3,775.00 | 1,175.00 | 76.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 225 | 195 | 190 | 157 | 135 | 161 | 192 | 157 | ||||
| Revenue/emp, $m | — | — | 0.23 | 0.24 | 0.24 | 0.24 | 0.17 | 0.24 | 0.25 | 0.31 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 52 | 47 | 46 | 38 | 23 | 39 | 48 | 49 | ||||
| Gross margin, % | — | — | 39.20 | 32.23 | 36.60 | 37.80 | 27.10 | 42.18 | 32.83 | 34.02 | |||||
| EBT | — | — | (15) | (17) | (21) | (18) | (17) | (16) | (29) | (21) | |||||
| EBT margin, % | — | — | (29.38) | (37.15) | (46.48) | (47.35) | (73.31) | (41.07) | (58.86) | (41.90) | |||||
| Net income | — | — | (15) | (17) | (22) | (18) | (17) | (16) | (29) | (21) | |||||
| Depreciation | — | — | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 10,573.47 | 7,953.56 | 5,628.66 | 4,064.41 | 929.80 | 664.20 | 702.35 | 38.47 | ||||
| Earnings | — | — | (3,625.00) | (3,500.00) | (2,625.00) | (1,925.00) | (1,400.00) | (275.00) | (416.00) | (29.44) | |||||
| Cash flow | — | — | (2,162.45) | (3,120.68) | (1,725.24) | (1,370.54) | (522.24) | (283.22) | (387.84) | (11.03) | |||||
| Capex | — | — | (288.57) | (126.61) | (63.66) | (22.26) | (3.92) | (11.98) | (54.01) | (0.88) | |||||
| Free cash flow | — | — | (2,451.02) | (3,247.29) | (1,788.90) | (1,392.80) | (526.16) | (295.20) | (441.86) | (11.91) | |||||
| Book value | — | — | 4,503.06 | 4,959.32 | 1,352.32 | 466.88 | 409.31 | 427.25 | 70.86 | 1.53 | |||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 1.63 | 0.66 | 0.44 | 0.34 | 1.12 | 1.47 | 0.10 | 0.03 | |||||
| P/B | — | — | 3.83 | 1.06 | 1.83 | 34.09 | 2.58 | 2.29 | 1.00 | 0.00 | |||||
| EV/Sales | — | — | 1.52 | 0.48 | 0.57 | 0.53 | 1.06 | 1.06 | 0.30 | 0.18 | |||||
| EV/FCF | — | — | (6.55) | (1.17) | (1.78) | (1.56) | (1.87) | (2.37) | (0.48) | (0.58) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (11) | (18) | (14) | (13) | (13) | (17) | (27) | (14) | ||||
| Capex | — | — | (1) | (1) | (1) | 0 | 0 | (1) | (4) | (1) | |||||
| Free cash flow | — | — | (12) | (19) | (15) | (13) | (13) | (17) | (30) | (15) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 16 | 23 | 17 | 1 | 24 | 36 | 11 | 5 | ||||
| Total debt | — | — | 0 | — | 11 | 13 | 16 | 14 | 14 | 14 | |||||
| Net debt | — | — | (9) | (12) | 2 | 7 | (1) | (16) | 10 | 7 | |||||
| Shareholders’ equity | — | — | 22 | 29 | 11 | 4 | 10 | 25 | 5 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (41.70) | (49.05) | (52.80) | (50.75) | (93.88) | (34.69) | (61.73) | (102.66) | ||||
| ROIC | — | — | (71.66) | (64.93) | (96.20) | (83.37) | (134.04) | (113.59) | (109.22) | (118.79) | |||||
| ROE | — | — | (74.72) | (81.17) | (106.65) | (311.44) | (665.05) | (95.22) | (191.94) | (1,620.81) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Sep 2024
Charts ten years each
Biolase, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADGM Adagio Medical Holdings, Inc. | $2.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.8M | 0.0× | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NXL Nexalin Technology, Inc. | $2.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| BIOLQ Biolase, Inc. | $2.3M | — (loss-making) | — (loss-making) | −0.65% (below 0%: shrinking) | n/m | −60.22% (below 0%: shrinking) | 40.39% | (6.41%) | |
| XAIR Beyond Air, Inc. | $2.2M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VJET Flyte Aviation, Inc. | $2.1M | — (loss-making) | — (loss-making) | +380.66% (above 0%: growing) | n/m | −26.70% (below 0%: shrinking) | 9.62% | (388.13%) | Compare |
| NUWE Nuwellis, Inc. | $2.0M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | — (loss-making) | — (loss-making) | +204.18% (above 0%: growing) | n/m | +76.40% (above 0%: growing) | 14.20% | (3.81%) | Compare |
| Median of peers | $2.2M | — | — | +14.14% | — | −10.98% | 13.47% | (110.11%) |
Biolase, Inc. (BIOLQ) key facts
- Strength: Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022.
- Biolase, Inc. (BIOLQ) is a Medical Devices company in the Healthcare sector.
- Return on equity was −1,620.8% and debt-to-equity -3.29.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −12.72 (distress zone) for fiscal 2023.